There are 821 subjects enrolled in this study. Of 414 randomized to the treatment arm, 49 (11.8%) developed COVId-19 within 14 days of randomization. Of the 407 randomized to the placebo arm, 58 (14.3) developed COVID-19 within 14 days of randomization.Question: estimate the standard error for the proportion from question 15 (what is the proportion of persons randomized to the hydroxychloroquine group who developed covid with 14 days of randomization)

able 2. Outcomes of Hydroxychloroquine Therapy for Postexposure Prophylaxis against Covid-19." Hydroxychloroquine Placebo Outcome (N =414) (N=407) P Value number (percent) Confirmed or probable Covid-19 49 (11.8) 58 (14.3) 0.35 Laboratory-confirmed diagnosis 11 (2.7) 9 (2.2) 0.82 Symptoms compatible with Covid-19 48 (11.6) 55 (13.5) 0.46 All new symptoms 57 (13.8) 59 (14.5) 0.84 Any hospitalization 1 (0.2) 1 (0.2) 0.99 Death 0 0